

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete if Known</i> Application Number 10/749,118-Conf. #3277 Filing Date December 30, 2003 First Named Inventor Richard L. BOYD Art Unit 1633 Examiner Name Q. Nguyen	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Attorney Docket Number 0286336.00151US1 (NOR-012CP2)	
Sheet	1	of	4		

[illegible]

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ² -Number ³ -Kind Code ⁴ (if known)	MM-DD-YYYY		
	BA	WO-03/051272	06-26-2003	Yeda Res & Dev et al.	
	BB	WO-02/30259	04-18-2002	Boyd	
	BC	WO-96/06642	03-07-1996	The General Hospital Corporation	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98a(2)(xiii)) because that application was filed after June 30, 2003 or is available in the IFW. * Applicant's unique citation designation number (optional). * See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP §61.04. * Enter office that issued the application. * Enter the name of the inventor, the inventor's address, the address of the agent, the address of the applicant, the name of the Employer, and the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/749,118-Conf. #3277		
		Filing Date	December 30, 2003		
		First Named Inventor	Richard L. BOYD		
		Art Unit	1633		
		Examiner Name	Q. Nguyen		
Sheet	2	of	4	Attorney Docket Number	0286336.00151US1 (NOR-012CP2)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	GREENWAY, Brian A., "Effect of Flutamide on Survival in Patients with Pancreatic Cancer: Results of a Prospective, Randomised, Double Blind Placebo Controlled Trial," BMJ Volume 316, June 27, 1998 (pages 1935-1938)	
	CB	JACOBSON, Jill et al., "Modulation of the Expression of Murine Lupus by Gonadotropin-Releasing Hormone Analogs," Endocrinology, Vol. 134, No. 6 (pages 2516-2523)	
	CC	NERI, Christian et al., "Direct Inhibiting Effects of [D-Trp ⁶] Gonadotropin-releasing Hormone on the Estrogen-sensitive Progression of Polyoma Virus-induced Mammary Tumors in Athymic Mice," Cancer Research 50, 5891-5897, September 15, 1990	
	CD	OLSEN, Nancy J., "Induction of Immature Thymocyte Proliferation after Castration of Normal Male Mice," Endocrinology, Vol. 134, No. 1, 1994 (pages 107-113)	
	CE	VAN GRIENSVEN, M., et al., "Differential Effects of Sex Hormones on Autoantibody Production and Proteinuria in Chronic Graft-Versus-Host Disease-Induced Experimental Lupus Nephritis," 1997 Blackwell Science Ltd., Clinical and Experimental Immunology, 107:254-260	
	CF	AUSTIN, Timothy W., et al., "Long-term Multilineage Expression in Peripheral Blood from a Moloney Murine Leukemia Virus Vector After Serial Transplantation of Transduced Bone Marrow Cells," Blood, Volume 95, Number 3, February 1, 2000, pages 829-836	
	CG	BBC News Health, "The Castration Cure," December 1998, pages 1-2	
	CH	MUSEY et al., "Cytotoxic-T-Cell Responses, Viral Load, and Disease Progression in Early Human Immunodeficiency Virus Type 1 Infection," New England Journal of Medicine, Vol. 337, 1997, pages 1267-1274	
	CI	NAKANISHI et al., "Cytotoxic T Cell Function in Fish," Developmental and Comparative Immunology, Vol. 26, 2002, pages 131-139	
	CJ	DEANESLY et al., "The Structure and Development of the Thymus in Fish, with Special Reference to Salmo Fario," Journal of Cell Science, Vol 281, 1927, pages 113-145	

Examiner Signature	Date Considered
-----------------------	--------------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/749,118-Conf. #3277		
		Filing Date	December 30, 2003		
		First Named Inventor	Richard L. BOYD		
		Art Unit	1633		
		Examiner Name	Q. Nguyen		
Sheet	3	of	4	Attorney Oocket Number	0286336.00151US1 (NOR-012CP2)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CK	BRAAK, H., "Stages in the Development of Parkinson's Disease-Related Pathology," Cell Tissue Res. Vol. 318, pages 121-134	
	CL	RINGHEIM, G.E., "Brain Inflammation, Cholesterol, and Glutamate as Interconneteced Participants int he Pathology of Alzheimer's Disease," Current Pharmaceutical Design, Vol. 12, 2002, pages 719-738	
	CM	SCHOFIELD, Richard S., et al., "Hormone Therapy in Men and Risk of Cardiac Allograft Rejection," Jouranlof Heart Lung Transplant, 2002, 21:493-495	
	CN	LIPSCOMB, et al., "Alterations in Bone-Marrow Cellularity Following Thymectomy in Rats," Experientia, 35:1401-1402, 1979	
	CO	HUDSON VM, "Rethinking Cystic Fibrosis Pathology: The Critical Role of Abnormal Reduced Glutathione Transport Caused by CFTR Mutation," 2001, Free Radical Biology and Med., Vol. 30, pages 1440-1461	
	CP	COLE-STRAUSS, A., "Correction of the Mutation Responsible for Sickle Cell Anemia by an RNA-DNA Oligonucleotide," 1996, Science, Vol. 273, pages 1386-1389	
	CQ	TAKAMI et al., "Influence of Gender on Allograft Rejection in a Rat Heart Transplant Model," J. Heart Lung Transplant, 1995, 14:529-536	
	CR	ANTUS et al., "Opposite effects of testosterone and estrogens on chronic allograft nephropathy," Transplant Institute, 2002, 15:494-501	
	CS	BOJAK et al., The Past, Present, and Future of HIV-Vaccine Development: A Critical Review," DDT 7:36-46, 2002	
	CT	COOPER, Max D., et al., "The Functions of the Thymus System and the Bursa System in the Chicken," Pillars of Immunology, The Journal of Experimental Medicine, Vol. 123, 1966, 35 pages	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/749,118-Conf. #3277		
		Filing Date	December 30, 2003		
		First Named Inventor	Richard L. BOYD		
		Art Unit	1633		
		Examiner Name	Q. Nguyen		
Sheet	4	of	4	Attorney Docket Number	0286336.00151US1 (NOR-012CP2)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/or country where published.	T ²
	CU	MWAU et al., "A Review of Vaccines for HIV Prevention," J. Gene Med. 5:3-10, 2003	
	CV	DESROSIER, R.C., "Prospects for an AIDS Vaccine," Nature Med. 10:221-223, 2004	
	CW	PANTALEO et al., "Correlates of Immune Protection in HIV-1 Infection: What We Know, What We Don't Know, What We Should Know," Nature Med. 10:806-810, 2004	
	CX	KONG, Fan-Kun et al., "Reversible Disruption of Thymic Function by Steroid Treatment," The Journal of Immunology, Copyright 2002 by The American Association of Immunologists, Inc., pages 6500 - 6505	
	CY	KONDO, Yasuhiro et al., "Effects of Estrogen Treatment During the Embryonic Period on Chick Antibody Production," Journal of Poultry Science, 41: 85-93, 2004	
	CZ	IMANISHI, Masaaki, "Induction of Tolerance by Intrathymic Injection of Donor Bone Marrow Cells and Its Mechanism," March 11, 1996, 9 pages	
	CA1	DUPONT, A., et al., "Combination Therapy with Flutamide and the LHRH Agonist [D-Trp ⁶ , des-Gly-NH ₂ ¹⁰] LHRH Ethylamide in Stage C Prostatic Carcinoma," British Journal of Urology (1993), 72, 629-634	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.